Comparison · NCT02490293-6c465fb2
Group A (Cephalosporin) vs Group B (Placebo): Number of Participants With Infectious Postoperative Complications
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A (Cephalosporin) vs Group B (Placebo): Number of Participants With Infectious Postoperative Complications. Trial comparisons, record NCT02490293-6c465fb2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02490293-6c465fb2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.086 | 0.0442 | 0.161 | wilson | |
| Risk in group 2 | 0.0737 | 0.0361 | 0.144 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0123 | -0.0698 | 0.0959 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.17 | 0.441 | 3.09 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.411 | 3.41 | log | |
| Number needed to treat, for one more participant with the outcome on Group A (Cephalosporin) than on Group B (Placebo) | 81.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A (Cephalosporin) | During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days.~Cephalosporin: During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days. | 8 | 93 | OG000 |
| Group 2 | Group B (Placebo) | During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days.~Placebo: During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days. | 7 | 95 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Infectious Postoperative Complications
- Description
Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to grade I Tokyo guidelines for acute cholecystitis or grade II Tokyo guidelines for acute cholecystitis except the evidence of gallbladder perforation, with antibiotics or placebo
- Time frame
- 30 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?
- NCT number
- NCT02490293
- Phases
- NA
- Conditions
- Acute Cholecystitis
- Interventions
- Cephalosporin, Placebo
- Lead sponsor
- Taeho Hong
- Results first posted
- 2017-04-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02490293?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02490293-6c465fb2